Following the decisions by the Colorado PDAB designating Cosentyx and Stelara as unaffordable to patients in Colorado, the EACH Coalition submitted comments to the board urging against proceeding with an upper payment limit rulemaking for the drugs.
The letter outlined concerns with upper payment limits including a lack of effectiveness in addressing patient needs and the possibility of increasing obstacles for patients seeking access to Cosentyx, Stelara, or other drugs in the class.
Despite objections from stakeholders, the Colorado board approved proceeding with an upper payment rulemaking during their February 23rd meeting. The rulemaking is expected to proceed in the fall of 2024.